Insmed's 'unprecedented' phase 2 PAH win sends stocks soaring as the race to phase 3 kicks off
Insmed hopes to bring treprostinil palmitil inhalation powder, a prodrug of United Therapeutics' blockbuster PAH mainstay Tyvaso, to phase 3 development by the end of this year.
Insmed hopes to bring treprostinil palmitil inhalation powder, a prodrug of United Therapeutics' blockbuster PAH mainstay Tyvaso, to phase 3 development by the end of this year.
